vTv Therapeutics

$2.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.18 (-7.38%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell VTVT and other stocks, options, and ETFs commission-free!

About VTVT

vTv Therapeutics Inc. Class A Common Stock, also called vTv Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC. The listed name for VTVT is vTv Therapeutics Inc. Class A Common Stock.

CEO

Stephen L. Holcombe

Employees

Headquarters

High Point, North Carolina

Founded

2015

Market Cap

206.30M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

3.39M

High Today

$2.48

Low Today

$2.15

Open Price

$2.39

Volume

1.74M

52 Week High

$4.75

52 Week Low

$1.44

VTVT Earnings

-$0.11

-$0.07

-$0.02

$0.02

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

$0.02 per share